LT 23 7 (Lidocaine 23% + Tetracaine 7%) Numbing Gel

For Research Use Only •

Original price was: $230.00.Current price is: $175.00.

LT 23 7 is a compounded, high-strength topical anesthetic formulated for temporary numbing of the skin prior to minimally invasive procedures. It combines two powerful local anesthetics:

  • Lidocaine (23%) – a rapid-onset amide-type anesthetic
  • Tetracaine (7%) – a long-acting ester-type anesthetic

Together, they provide deep dermal anesthesia, suitable for cosmetic, dermatologic, laser, tattoo, or aesthetic procedures. The dual-mechanism blocks sodium channels in peripheral nerves, preventing pain signal transmission.


  • 1 x 100ml sterile airless pump container or dispensing tube
  • Active ingredients:
    • Lidocaine: 23%
    • Tetracaine: 7%
  • Inactive base: gel-formulated carrier for enhanced transdermal absorption
  • Non-greasy, fast-acting, and easy to remove
  • Designed for topical external use only

LT 23 7 is a compounded, high-strength topical anesthetic formulated for temporary numbing of the skin prior to minimally invasive procedures. It combines two powerful local anesthetics:

  • Lidocaine (23%) – a rapid-onset amide-type anesthetic
  • Tetracaine (7%) – a long-acting ester-type anesthetic

Together, they provide deep dermal anesthesia, suitable for cosmetic, dermatologic, laser, tattoo, or aesthetic procedures. The dual-mechanism blocks sodium channels in peripheral nerves, preventing pain signal transmission.

Lidocaine and tetracaine both work by blocking voltage-gated sodium channels in the peripheral nervous system. This inhibits the generation and conduction of nerve impulses, resulting in a temporary loss of sensation at the application site.

  • Lidocaine: Rapid onset, medium duration
  • Tetracaine: Slower onset, longer duration, enhances depth of penetration

Their synergistic action provides both fast-acting and sustained anesthetic effect.

When used appropriately, LT 23 7 is generally safe and effective. However, topical anesthetics can be absorbed systemically in large quantities or over prolonged periods.

Possible side effects:

  • Mild skin irritation, itching, or redness
  • Temporary blanching or erythema at application site
  • Numbness or tingling persisting beyond removal
  • Rare: headache, dizziness, or palpitations (if systemic absorption occurs)
  • Allergic reactions (rare, more common with tetracaine)

Always perform a patch test on new users and avoid use on compromised skin.

Potential Benefits:
  • Rapid and deep numbing of skin
  • Ideal for laser, microneedling, RF, injections, PRP, tattoos, waxing, and dermal fillers
  • Reduces procedure-related discomfort
  • Enhances client comfort and satisfaction
  • Minimizes the need for injectable anesthetics in many cases
⚠️ Side Effects:
  • Redness, swelling, or irritation at site
  • Rare systemic effects if overused
  • Risk of methemoglobinemia if used with other anesthetic agents
  • Allergic reactions, especially to tetracaine (ester class)
  • Do not use on broken, infected, or inflamed skin
  • Avoid use in patients with known allergies to amide or ester anesthetics
  • Not recommended for large surface area applications
  • Do not occlude for longer than 60 minutes
  • Use caution in individuals with hepatic impairment, heart disease, or seizure disorders
  • Not for internal, ophthalmic, or mucosal use
  • Avoid use with other topical anesthetics, especially benzocaine or prilocaine, to reduce risk of toxicity
  • Caution when used alongside antiarrhythmic drugs (e.g., amiodarone, mexiletine)
  • Alcohol or sedative use may amplify systemic CNS depressant effects

Use of high-concentration topical anesthetics in pregnancy should be limited to medically necessary procedures under supervision. While lidocaine is Category B, tetracaine lacks sufficient safety data. Avoid use during breastfeeding on areas that may contact the infant (e.g., chest, breast).

LT 23 7 is not intended for pediatric use. High concentrations of lidocaine and tetracaine can lead to serious adverse effects in children, including methemoglobinemia or CNS toxicity. Use only under pediatric supervision, and never on infants.

While lidocaine and tetracaine are FDA-approved active ingredients, this compounded 23%/7% formulation is not FDA-approved as a commercial drug. It is made under licensed compounding pharmacy protocols and used under physician or practitioner direction.

  1. Becker DE, et al. “Local anesthetics: review of pharmacological considerations.” Anesthesia Progress.
  2. Klein JA. “Systemic toxicity from local anesthetics.” Dermatologic Surgery.
  3. FDA Drug Database – Lidocaine and Tetracaine safety guidelines
  4. Clinical guidelines on topical anesthetic use in cosmetic and dermatologic procedures
  5. Alam M, et al. “Use of topical anesthetics in dermatology: safety and efficacy.” J Am Acad Dermatol.

Out of stock

Category: Tag:

Please verify you are 21 years or older to enter.

WARNING: We require visitors to be 21 years old or over, please verify below. Are you over 21 years of age or over?